News from EAU20, ISTH, and AACR's COVID-19 & Cancer meeting: Surgery in renal cell cancer, bevacizumab in HHT, and nosocomial COVID-19

Tuesday, August 4, 2020

Subscribe to Blood & Cancer: Apple Podcasts, Spotify, Google Podcasts

This week in HemOnc News:

  1. Higher death rate seen in cancer patients with nosocomial COVID-19
    Article: https://bit.ly/2XjRLDq
    Source: https://bit.ly/3goLGgF
  2. Robotic renal surgery bests open partial nephrectomy
    Article: https://bit.ly/2PhHS4M
    Source: https://bit.ly/3gqXXBd

  3. Large cohort study: Bevacizumab safe, effective for severe HHT bleeds
    Article: https://bit.ly/2XpuZdj
    Source: https://bit.ly/2BXHVQg

For more MDedge Podcasts, click this link: http://bit.ly/2CfnY52

Email the show: podcasts@mdedge.com

Follow Dr. David Henry on Twitter @DavidHenryMD

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.